BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 17156987)

  • 1. Effervescent dry powder for respiratory drug delivery.
    Ely L; Roa W; Finlay WH; Löbenberg R
    Eur J Pharm Biopharm; 2007 Mar; 65(3):346-53. PubMed ID: 17156987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of inhalable dry powder formulation of basic fibroblast growth factor.
    Ibrahim BM; Jun SW; Lee MY; Kang SH; Yeo Y
    Int J Pharm; 2010 Jan; 385(1-2):66-72. PubMed ID: 19853028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug release study of large hollow nanoparticulate aggregates carrier particles for pulmonary delivery.
    Hadinoto K; Zhu K; Tan RB
    Int J Pharm; 2007 Aug; 341(1-2):195-206. PubMed ID: 17467934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles.
    Azarmi S; Tao X; Chen H; Wang Z; Finlay WH; Löbenberg R; Roa WH
    Int J Pharm; 2006 Aug; 319(1-2):155-61. PubMed ID: 16713150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery.
    Pilcer G; Vanderbist F; Amighi K
    Int J Pharm; 2009 Jan; 365(1-2):162-9. PubMed ID: 18782609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants.
    Cheow WS; Ng ML; Kho K; Hadinoto K
    Int J Pharm; 2011 Feb; 404(1-2):289-300. PubMed ID: 21093560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical characteristics and aerosol performance of naringin dry powders for pulmonary delivery prepared by spray-drying.
    Sansone F; Aquino RP; Del Gaudio P; Colombo P; Russo P
    Eur J Pharm Biopharm; 2009 May; 72(1):206-13. PubMed ID: 18996478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel sustained release microspheres for pulmonary drug delivery.
    Cook RO; Pannu RK; Kellaway IW
    J Control Release; 2005 May; 104(1):79-90. PubMed ID: 15866336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhalation performance of pollen-shape carrier in dry powder formulation with different drug mixing ratios: comparison with lactose carrier.
    Hassan MS; Lau R
    Int J Pharm; 2010 Feb; 386(1-2):6-14. PubMed ID: 19922775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
    Minne A; Boireau H; Horta MJ; Vanbever R
    Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients.
    Razavi Rohani SS; Abnous K; Tafaghodi M
    Int J Pharm; 2014 Apr; 465(1-2):464-78. PubMed ID: 24560646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids.
    Hadinoto K; Phanapavudhikul P; Kewu Z; Tan RB
    Int J Pharm; 2007 Mar; 333(1-2):187-98. PubMed ID: 17084567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
    Marriott C; MacRitchie HB; Zeng XM; Martin GP
    Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery.
    Sweeney LG; Wang Z; Loebenberg R; Wong JP; Lange CF; Finlay WH
    Int J Pharm; 2005 Nov; 305(1-2):180-5. PubMed ID: 16242277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation.
    Adi H; Larson I; Stewart PJ
    Int J Pharm; 2007 Jun; 337(1-2):229-38. PubMed ID: 17303354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneously manufactured nano-in-micro (SIMANIM) particles for dry-powder modified-release delivery of antibodies.
    Kaye RS; Purewal TS; Alpar HO
    J Pharm Sci; 2009 Nov; 98(11):4055-68. PubMed ID: 19189420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel dry powder inhaler formulation of glucagon with addition of citric acid for enhanced pulmonary delivery.
    Onoue S; Yamamoto K; Kawabata Y; Hirose M; Mizumoto T; Yamada S
    Int J Pharm; 2009 Dec; 382(1-2):144-50. PubMed ID: 19703531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate.
    Thi TH; Danède F; Descamps M; Flament MP
    Eur J Pharm Biopharm; 2008 Sep; 70(1):380-8. PubMed ID: 18504120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entrainment of lactose inhalation powders: a study using laser diffraction.
    Watling CP; Elliott JA; Cameron RE
    Eur J Pharm Sci; 2010 Jul; 40(4):352-8. PubMed ID: 20417708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.